Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2015

Open Access 01-05-2015

Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis

Authors: Kathleen Lang, Aarti A. Patel, Michael Munsell, Brahim K. Bookhart, Samir H. Mody, Jeff R. Schein, Joseph Menzin

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2015

Login to get access

Abstract

The objective of this study was to assess deep vein thrombosis and pulmonary embolism (DVT/PE) recurrence rates and resource utilization among patients with an initial DVT or PE event across multiple payer perspectives. Retrospective analyses were performed using a software tool that analyzes health plan claims to evaluate treatment patterns and resource utilization for various cardiovascular conditions. Six databases were analyzed from three payer perspectives (Commercial, Medicare, and Medicaid). Patients were ≥18 years old with a primary diagnosis of DVT or PE associated with an inpatient and/or emergency room claim, had received an antithrombotic within 7 days before or 14 days after index, and had no diagnosis of atrial fibrillation during follow-up. Outcomes were assessed over a 1 year period following index. More PE patients were hospitalized for their index event than DVT patients (42–59 % DVT and 69–86 % PE) and had longer mean length of stay (2.35–2.95 days DVT and 3.26–3.76 days PE). Recurrent event rates among PE patients (12–32 %) were higher than those for DVT patients (6–16 %) across all payers. The highest rate of recurrence was observed among the Medicaid population [23 % overall (VTE); 16 % DVT; 32 % PE]. All-cause hospitalization in the year following their VTE episode occurred in 23–67 % DVT patients and 30–68 % PE patients. Medicaid had the highest proportion of patients with hospitalizations and ER visits. Recurrent VTE events and all-cause hospitalizations are relatively common, especially for patients who had a PE, and among those in the Medicaid payer population.
Literature
1.
go back to reference Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29(3):298–310CrossRefPubMed Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29(3):298–310CrossRefPubMed
2.
go back to reference Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125(1):1–7CrossRefPubMed Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125(1):1–7CrossRefPubMed
3.
go back to reference Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293(19):2352–2361CrossRefPubMed Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293(19):2352–2361CrossRefPubMed
4.
go back to reference Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMed Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162(11):1245–1248CrossRefPubMed
5.
go back to reference Lefebvre P, Laliberte F, Nutescu EA et al (2012) All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 18(5):363–374PubMed Lefebvre P, Laliberte F, Nutescu EA et al (2012) All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 18(5):363–374PubMed
6.
go back to reference Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125(1):1–7CrossRefPubMed Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125(1):1–7CrossRefPubMed
7.
go back to reference Rodger MA, Kahn SR, Wells PS et al (2008) Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179(5):417–426CrossRefPubMedCentralPubMed Rodger MA, Kahn SR, Wells PS et al (2008) Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179(5):417–426CrossRefPubMedCentralPubMed
8.
go back to reference Prandoni P, Villalta S, Bagatella P et al (1997) The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 82(4):423–428PubMed Prandoni P, Villalta S, Bagatella P et al (1997) The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 82(4):423–428PubMed
9.
go back to reference Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L (2005) Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 11(8):663–673PubMed Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L (2005) Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 11(8):663–673PubMed
10.
go back to reference Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13(6):475–486PubMed Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13(6):475–486PubMed
13.
go back to reference Boulet SL, Amendah D, Grosse SD, Hooper WC (2012) Health care expenditures associated with venous thromboembolism among children. Thromb Res 129(5):583–587CrossRefPubMed Boulet SL, Amendah D, Grosse SD, Hooper WC (2012) Health care expenditures associated with venous thromboembolism among children. Thromb Res 129(5):583–587CrossRefPubMed
14.
15.
go back to reference van Bellen B, Prins M, Bamber L, Wang M, Lensing. Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program. Presented at the American Society of Hematology (ASH) 54th Annual Meeting and Exposition, Atlanta, GA, USA, December 8–11, 2012 van Bellen B, Prins M, Bamber L, Wang M, Lensing. Reduction in Initial Length of Stay with Rivaroxaban Single-Drug Regimen versus LMWH-VKA Standard of Care: Findings from the EINSTEIN Trial Program. Presented at the American Society of Hematology (ASH) 54th Annual Meeting and Exposition, Atlanta, GA, USA, December 8–11, 2012
16.
go back to reference White R (2003) The Epidemiology of Venous Thromboembolism. Circulation 107:4–8CrossRef White R (2003) The Epidemiology of Venous Thromboembolism. Circulation 107:4–8CrossRef
17.
go back to reference Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D (2010) Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 27(9):623–633CrossRefPubMed Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D (2010) Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 27(9):623–633CrossRefPubMed
18.
go back to reference Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101–108CrossRefPubMedCentralPubMed Khorana AA, Dalal MR, Lin J, Connolly GC (2013) Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 5:101–108CrossRefPubMedCentralPubMed
19.
go back to reference Misky GJ, Manheim JC, Zehnder N et al (2011) Health care disparities in the acute management of venous thromboembolism based on insurance status in the U.S. J Thromb Thrombolysis 32(4):393–398CrossRefPubMed Misky GJ, Manheim JC, Zehnder N et al (2011) Health care disparities in the acute management of venous thromboembolism based on insurance status in the U.S. J Thromb Thrombolysis 32(4):393–398CrossRefPubMed
Metadata
Title
Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis
Authors
Kathleen Lang
Aarti A. Patel
Michael Munsell
Brahim K. Bookhart
Samir H. Mody
Jeff R. Schein
Joseph Menzin
Publication date
01-05-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-014-1108-z

Other articles of this Issue 4/2015

Journal of Thrombosis and Thrombolysis 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.